Autonomix Medical (NASDAQ:AMIX) Upgraded to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of Autonomix Medical (NASDAQ:AMIX) from a strong sell rating to a sell rating in a research note released on Sunday,Wall Street Zen reports.

Several other equities analysts have also weighed in on AMIX. Weiss Ratings raised shares of Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. Zacks Research upgraded shares of Autonomix Medical to a “hold” rating in a research note on Tuesday, June 2nd. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $42.00.

Autonomix Medical Stock Performance

AMIX opened at $4.59 on Friday. The stock has a market cap of $4.45 million, a price-to-earnings ratio of -0.11 and a beta of -1.00. Autonomix Medical has a 1 year low of $2.44 and a 1 year high of $32.55. The stock has a fifty day moving average price of $6.11 and a 200 day moving average price of $7.43.

Autonomix Medical (NASDAQ:AMIX) last issued its earnings results on Wednesday, August 12th. The company reported ($5.02) earnings per share for the quarter, topping the consensus estimate of ($6.40) by $1.38. As a group, sell-side analysts forecast that Autonomix Medical will post -20.17 earnings per share for the current fiscal year.

About Autonomix Medical

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.